Brian L. Koopman is the current CEO and Principal Financial Officer at Utah Medical Products, Inc. (UTMD), a company he joined in 2006. He has been steering the financial strategy of UTMD since his appointment as Principal Financial Officer in...

Brian L. Koopman is the current CEO and Principal Financial Officer at Utah Medical Products, Inc. (UTMD), a company he joined in 2006. He has been steering the financial strategy of UTMD since his appointment as Principal Financial Officer in 2018. Born in 1983, Brian has a background in finance, emphasizing how he blends technical expertise with leadership in a competitive market. What’s interesting is that he has seen his compensation grow over the years, with a total compensation of $165,319 in 2023, including a salary and stock options, but no bonuses awarded. Brian's strategy focuses on aligning performance with company goals, which is key in the medical products industry. He also has a track record of significant stock option grants, illustrating the trust placed in him by the company, along with a hands-on approach to managing finances. Notably, Brian has engaged in consistent insider trading activities, showing his commitment and financial stake in the company’s success, with trades amounting to over $400,000 in value since 2019. He did not exercise any options in 2023, but he has options vesting over several years, reflecting a long-term outlook for both himself and shareholders. Brian’s role in UTMD has positioned him as a crucial player in the medical technology field, and his financial decisions impact the company’s future and success.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Utah Medical Products CEOs

U

Brian L. Koopman

CEO of Utah Medical Products

Education

Not specified

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

January 1, 1983 - 42 years ago

CEO of Utah Medical Products for

7 years 0 months (Apr 2018 - Present)

Previous Experience

Controller since 2006

Rivals

Competitors/colleagues of Brian L. Koopman

Holdings

See how much did Brian L. Koopman make over time.

Brian L. Koopman has consistently shown a solid financial commitment to Utah Medical Products through his stock holdings. His insider trading activity reflects a strong belief in the company's potential, with total trades exceeding $400,000 in the last few years....

Brian L. Koopman has consistently shown a solid financial commitment to Utah Medical Products through his stock holdings. His insider trading activity reflects a strong belief in the company's potential, with total trades exceeding $400,000 in the last few years. In 2023, Brian was granted 500 stock options priced at $77.07 each, vesting over four years. Despite market fluctuations, his stock portfolio reveals strategic engagement, maintaining about 4,956 shares directly and indirectly. His approach illustrates both confidence in UTMD’s trajectory and a focus on long-term growth and shareholder value, highlighting his vested interest in the company's performance.

Total Stock Sold

$32.00K

UTMD

$32.00K

300 UTMD shares

What if they kept their stock?

If Brian L. Koopman didn't sell their stock, today they would have:
Extra UTMD300 shares worth $26.61K.
This is -16.85% and $5.39K less than what they got when they sold the stock.

Charitable Transactions

UTMD

175 shares

UTMD

Recent Charitable Transactions

UTMD

$3.58K

UTMD at $71.61/share

Jul 18, 2024

Charity

UTMD

$5.66K

UTMD at $94.31/share

Jun 15, 2023

Charity

UTMD

$5.78K

UTMD at $88.94/share

Oct 31, 2022

Charity

Insider Trading

See recent insider trades of Brian L. Koopman.

UTMD

$3.58K

UTMD at $71.61/share

Jul 18, 2024

Charity

UTMD

$5.66K

UTMD at $94.31/share

Jun 15, 2023

Charity

UTMD

$5.78K

UTMD at $88.94/share

Oct 31, 2022

Charity

UTMD

$32.10K

UTMD at $107.00/share

Nov 5, 2019

Sale

Compensation History

See how much did Brian L. Koopman make over time.

In 2023, Brian L. Koopman received total compensation of $165,319, including a salary of $131,830 and $4,569 in other compensation through benefits like 401(k) matching. Notably, he received no bonuses this year, marking a shift in compensation structures. His total compensation illustrates the company’s philosophy of aligning executive pay with performance while navigating challenges in the medical industry. Comparatively, his compensation has steadily increased since he became Principal Financial Officer. This emphasizes how the company is focusing on retaining talent while ensuring its financial health resources are well-managed. Brian's reporting showcases UTMD’s approach to executive compensation, relying less on bonuses and more on structured stock options to drive long-term performance.

Year

2023

Total Compensation

$136.40K

Salary

$131.83K

Board Justification

The compensation philosophy aligns with company performance and aims to attract and retain talent while rewarding performance.

Bonus

$0.00

Board Justification

No bonus was awarded for the year 2023.

Other

$4.57K

Board Justification

Includes 401(k) matching contributions and reimbursements under the pet insurance plan.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023.

Performance Metrics

Compensation is based on financial and non-financial performance metrics, including net sales, gross profit margin, and return on equity.

Other Utah Medical Products CEOs

Here are other CEOs of Utah Medical Products

Paul O. Richins

Ex-CEO of Utah Medical Products

April 2006 - April 2018